Open access
Sep 2026
Clinical and Functional Profile of Patients with Severe Eosinophilic Asthma with Rapid Response to Benralizumab Therapy (Super-Responders): A Single-Center Retrospective Study.
Shorter disease duration and better baseline symptom control were identified as predictors of rapid achievement of clinical remission to benralizumab therapy in patients with severe eosinophilic asthma, whereas T2-inflammatory markers did not demonstrate clinical significance.
Irina V. Mayorova, O. Mukhina, M. Lebedkina et al.
· Russian Journal of Allergy · 0 citations